MiMedx Group/$MDXG

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Ticker

$MDXG
Sector
Primary listing

Employees

837

MiMedx Group Metrics

BasicAdvanced
$1.1B
34.11
$0.21
1.74
-

What the Analysts think about MiMedx Group

Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.

Bulls say / Bears say

MiMedx delivered record Q2 2025 net sales of $99 million, up 13% year-over-year and surpassing consensus estimates, driven by double-digit growth in both its Wound and Surgical franchises, signaling robust demand for its core products (Reuters).
The company achieved a record adjusted EBITDA of $24 million (25% of net sales) and increased its cash balance by $12 million to $119 million in Q2 2025, reflecting strong operational efficiency and healthy cash generation (GlobeNewswire).
Management raised its full-year 2025 net sales growth outlook to low double-digits following the strong Q2 performance, demonstrating confidence in sustaining balanced, double-digit growth for the remainder of the year (GlobeNewswire).
CMS’s CY2026 Physician Fee Schedule proposal would replace Medicare’s current ASP‐based skin substitute reimbursement with a flat rate of $125.38 per cm² versus current OPPS HOPD bundled payments of about $1,738 per treatment, risking more than a 90% cut in reimbursement for MiMedx’s high‐cost biologics and compressing future revenue and margins (Investing.com).
Selling, general and administrative expenses rose 16% year‐over‐year to $64 million in Q2 2025, driven by higher commissions and legal costs, suggesting ongoing expense pressures that could limit margin expansion (GlobeNewswire (Reuters)).
Q2 2025 net income of $9.62 million on $99 million in net sales implies a net margin of around 9.7%, highlighting limited bottom‐line leverage despite an 81% gross margin and underscoring significant expense drag (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MiMedx Group Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MiMedx Group Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MDXG

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs